Retroperitoneal Lymph Node Dissection in Colorectal Cancer with Lymph Node Metastasis: A Systematic Review
Cancers · 10.01.2023 · 15 (2) · 455
DOI: 10.3390/cancers15020455 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 10.01.2023. Verfasst von Michael G Fadel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Imperial Biomedical Research Centre, National Institute for Health Research (NIHR), Imperial Biomedical Research Centre.
Abstract (Originalsprache)
The benefits and prognosis of RPLND in CRC have not yet been fully established. This systematic review aimed to evaluate the outcomes for CRC patients with RPLNM undergoing RPLND. A literature search of MEDLINE, EMBASE, EMCare, and CINAHL identified studies from between January 1990 and June 2022 that reported data on clinical outcomes for patients who underwent RPLND for RPLNM in CRC. The following primary outcome measures were derived: postoperative morbidity, disease free-survival (DFS), overall survival (OS), and re-recurrence. Nineteen studies with a total of 541 patients were included. Three hundred and sixty-three patients (67.1%) had synchronous RPLNM and 178 patients (32.9%) had metachronous RPLNM. Perioperative chemotherapy was administered in 496 (91.7%) patients. The median DFS was 8.6–38.0 months and 5-year DFS was 24.4% (10.0–60.5%). The median OS was 25.0–83.0 months and 5-year OS was 47.0% (15.0–87.5%). RPLND is a feasible treatment option with limited morbidity and possible oncological benefit for both synchronous and metachronous RPLNM in CRC. Further prospective clinical trials are required to establish a better evidence base for RPLND in the context of RPLNM in CRC and to understand the timing of RPLND in a multimodality pathway in order to optimise treatment outcomes for this group of patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK.
- Department of Colorectal Surgery, Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
- Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
- Colorectal Unit, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
- Department of Colorectal Surgery, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
- Department of Academic Urology, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
ORCID-Profile: Michael G Fadel, Mosab Ahmed, Gianluca Pellino, Christos Kontovounisios
Förderung
- NIHR Imperial Biomedical Research Centre
- National Institute for Health Research (NIHR)
- Imperial Biomedical Research Centre
- NIHR Marsden Biomedical Research Centre
Zitieren
APA
Fadel, M. G., Ahmed, M., Pellino, G., Rasheed, S., Tekkis, P., Nicol, D., Kontovounisios, C., & Mayer, E. (2023). Retroperitoneal Lymph Node Dissection in Colorectal Cancer with Lymph Node Metastasis: A Systematic Review. Cancers, 15(2), 455. https://doi.org/10.3390/cancers15020455
Vancouver
Fadel MG, Ahmed M, Pellino G, Rasheed S, Tekkis P, Nicol D, et al. Retroperitoneal Lymph Node Dissection in Colorectal Cancer with Lymph Node Metastasis: A Systematic Review. Cancers. 2023;15(2):455. doi:10.3390/cancers15020455
BibTeX
@article{Fadel2023,
author = {Fadel, Michael G and Ahmed, Mosab and Pellino, Gianluca and Rasheed, Shahnawaz and Tekkis, Paris and Nicol, David and Kontovounisios, Christos and Mayer, Erik},
title = {Retroperitoneal Lymph Node Dissection in Colorectal Cancer with Lymph Node Metastasis: A Systematic Review},
journal = {Cancers},
year = {2023},
volume = {15},
number = {2},
pages = {455},
doi = {10.3390/cancers15020455}
}
EUVIMED